Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch–Belgian Cooperative Trial for Haemato-Oncology (HOVON).

MLA

Thielen, Noortje, et al. “Imatinib Discontinuation in Chronic Phase Myeloid Leukaemia Patients in Sustained Complete Molecular Response: A Randomised Trial of the Dutch–Belgian Cooperative Trial for Haemato-Oncology (HOVON).” European Journal of Cancer, vol. 49, no. 15, Oct. 2013, pp. 3242–46. EBSCOhost, https://doi.org/10.1016/j.ejca.2013.06.018.

APA

Thielen, N., van der Holt, B., Cornelissen, J. J., Verhoef, G. E. G., Gussinklo, T., Biemond, B. J., Daenen, S. M. G., Deenik, W., van Marwijk Kooy, R., Petersen, E., Smit, W. M., Valk, P. J. M., Ossenkoppele, G. J., & Janssen, J. J. W. M. (2013). Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch–Belgian Cooperative Trial for Haemato-Oncology (HOVON). European Journal of Cancer, 49(15), 3242–3246. https://doi.org/10.1016/j.ejca.2013.06.018

Chicago

Thielen, Noortje, Bronno van der Holt, Jan J. Cornelissen, Gregor E.G. Verhoef, Titia Gussinklo, Bart J. Biemond, Simon M.G. Daenen, et al. 2013. “Imatinib Discontinuation in Chronic Phase Myeloid Leukaemia Patients in Sustained Complete Molecular Response: A Randomised Trial of the Dutch–Belgian Cooperative Trial for Haemato-Oncology (HOVON).” European Journal of Cancer 49 (15): 3242–46. doi:10.1016/j.ejca.2013.06.018.